Last updated: September 24, 2026
Nitrofurantoin monohydrate/macrocrystals is a mature immediate-release oral antibiotic sold primarily as 100 mg capsules for acute uncomplicated urinary tract infections. The commercial opportunity is concentrated in formulation performance, supply reliability, differentiated dosage forms, private-label manufacturing, and geographic expansion rather than in new chemical-entity exclusivity. The reference product, Macrobid, has no meaningful current exclusivity barrier that prevents approved generic competition in the United States. [1,2]
What is nitrofurantoin monohydrate/macrocrystals?
Nitrofurantoin monohydrate/macrocrystals combines two physical forms of nitrofurantoin in a single oral capsule. The product is designed to improve gastrointestinal tolerability relative to older nitrofurantoin formulations while delivering urinary antibacterial concentrations.
Macrobid is labeled for the treatment of acute uncomplicated cystitis caused by susceptible strains of Escherichia coli, Enterobacter species, Klebsiella species, Enterococcus species, and Staphylococcus saprophyticus. The labeled adult regimen is 100 mg twice daily for seven days, taken with food. [1]
| Attribute |
Product information |
| Active ingredient |
Nitrofurantoin monohydrate/macrocrystals |
| Common strength |
100 mg |
| Dosage form |
Hard gelatin capsule |
| Primary indication |
Acute uncomplicated cystitis |
| Reference product |
Macrobid |
| U.S. regulatory pathway |
Abbreviated New Drug Application for generics |
| Administration |
With food |
| Main commercial challenge |
Bioequivalent performance, tolerability, and low-cost supply |
| Main formulation variables |
Particle size, polymorphic form, blend uniformity, capsule fill, dissolution, food effect |
Nitrofurantoin is not appropriate for pyelonephritis or systemic infections because it does not achieve adequate therapeutic tissue concentrations outside the urinary tract. Renal function is a central prescribing and labeling consideration. [1]
What excipients are used in nitrofurantoin monohydrate/macrocrystals capsules?
The reference Macrobid formulation uses conventional capsule excipients, with lactose monohydrate, corn starch, magnesium stearate, povidone, talc, and capsule-shell components identified in the U.S. labeling. The formulation also uses coloring agents in the capsule shell. [1]
Reference excipient architecture
| Formulation function |
Typical excipient or component |
Commercial role |
| Dilution and fill-weight control |
Lactose monohydrate |
Provides bulk and supports capsule-content uniformity |
| Disintegration and wicking |
Corn starch |
Promotes breakup and wetting of the powder bed |
| Granulation or binding |
Povidone |
Supports particle agglomeration and mechanical integrity |
| Lubrication |
Magnesium stearate |
Improves manufacturing flow and capsule filling |
| Glidancy and anti-adherence |
Talc |
Supports powder handling and processing |
| Capsule shell |
Gelatin, titanium dioxide, iron oxides |
Provides dosage-form identity and protection |
| Color |
Yellow and other approved colorants |
Supports product differentiation and visual identification |
The key technical issue is not the excipient list alone. Nitrofurantoin performance depends on the interaction between particle size, active-ingredient physical form, powder density, wetting, capsule fill, and dissolution. A generic manufacturer can match the qualitative excipient profile and still fail to reproduce the reference product’s in vitro and in vivo performance.
How does excipient selection affect nitrofurantoin bioequivalence?
Excipient selection affects nitrofurantoin through dissolution rate, gastrointestinal wetting, powder dispersion, capsule rupture, and food-dependent absorption. The active ingredient is poorly water-soluble, so seemingly minor changes in powder processing or hydrophilic excipient content can alter the dissolution profile.
Critical quality attributes
A commercial development program should monitor:
- Particle-size distribution of the monohydrate and macrocrystalline fractions.
- Water content and hydrate stability.
- Polymorphic or solid-state behavior.
- Blend uniformity for the two nitrofurantoin fractions.
- Capsule fill weight and content uniformity.
- Dissolution in discriminatory media.
- Food-effect behavior.
- Impurity and degradation profiles.
- Powder flow, segregation, and electrostatic behavior.
- Capsule-shell disintegration.
The formulation should be developed around a design space rather than a nominal excipient formula. Lactose and starch levels, for example, can change bulk density and capsule fill behavior. Povidone can improve granule cohesion but may slow disintegration if used excessively. Magnesium stearate can reduce wetting when over-lubrication occurs.
Excipient risks
The principal excipient risks are:
- Lactose intolerance or concern about dairy-derived materials.
- Maillard-type compatibility concerns involving lactose and amine-containing compounds.
- Excessive hydrophobic lubrication from magnesium stearate.
- Variability in starch particle size and moisture.
- Talc quality, mineral contamination, and supplier qualification.
- Gelatin source and animal-origin restrictions.
- Colorant restrictions in specific jurisdictions.
- Capsule brittleness or cross-linking under high humidity or elevated temperature.
A lactose-free or vegetarian capsule opportunity exists, but any reformulation requires comparative dissolution, stability, and bioequivalence work. A simple substitution of lactose with microcrystalline cellulose, mannitol, or dibasic calcium phosphate may change capsule density and release behavior.
What excipient strategies create commercial opportunities?
The strongest opportunity is a robust, scalable formulation that reduces manufacturing variability without changing the approved clinical use. Excipient differentiation is commercially relevant when it improves quality, patient acceptability, regulatory reach, or manufacturing economics.
1. Lactose-free formulations
Lactose-free capsules could address patients and markets that avoid lactose-containing medicines. Candidate fillers include microcrystalline cellulose, mannitol, pregelatinized starch, and selected grades of dibasic calcium phosphate.
The key development requirements are:
- Equivalent capsule fill and powder density.
- Comparable dissolution under fasted and fed conditions.
- No increase in gastric intolerance.
- Stable moisture profile.
- Compatible manufacturing flow.
- A defensible regulatory rationale for the formulation change.
The market is unlikely to support a premium solely for lactose removal in a low-cost antibiotic. The opportunity is stronger in hospital, institutional, export, and specialty-pharmacy channels where formulary requirements or excipient restrictions influence procurement.
2. Vegetarian and plant-based capsule shells
Hydroxypropyl methylcellulose capsules can replace gelatin shells. This can support vegetarian positioning, simplify animal-origin documentation, and improve acceptability in selected geographic markets.
Potential technical issues include:
- Different moisture transmission.
- Different capsule-shell dissolution.
- Compatibility with the powder blend.
- Greater shell brittleness under certain storage conditions.
- Changes in machine performance and defect rates.
A plant-based capsule is more likely to create a procurement or geographic advantage than a large retail price premium.
3. Improved swallowability
Capsule-size reduction, a smaller fill-volume design, or a different shell material could improve patient acceptability. Nitrofurantoin is generally used in outpatient settings, and adherence depends on twice-daily administration with food for seven days.
Commercially viable approaches include:
- Higher-density powder engineering.
- Reduced excipient volume.
- Smaller capsule shell using a controlled fill process.
- Taste-masked multiparticulates for patients unable to swallow capsules.
- Unit-dose blister packaging with food-administration instructions.
Dose compression must not compromise dissolution or content uniformity.
4. Moisture-control excipient systems
A moisture-robust formulation may reduce stability failures in tropical and subtropical markets. The strategy can combine low-moisture excipients, improved container-closure systems, desiccants, and validated packaging.
The commercial value is highest where:
- Distribution involves high humidity.
- Cold-chain infrastructure is limited.
- Products are repackaged by wholesalers.
- Stability failures create recurring inventory losses.
Packaging changes may provide faster regulatory and development benefits than a major excipient redesign.
5. Modified-release or lower-frequency products
A once-daily or extended-release nitrofurantoin product could reduce dosing frequency, but this is a substantially higher-risk program. The product would require new pharmacokinetic, clinical, and regulatory work rather than a routine generic-development pathway.
The commercial case depends on demonstrating a meaningful adherence or tolerability advantage. A modified-release product may also face new patent filings covering formulation, release profile, dosing regimen, or urinary exposure.
What patents protect nitrofurantoin monohydrate/macrocrystals?
The core active ingredient is long off patent, and the principal Macrobid formulation patents have expired. Current generic competition is therefore governed primarily by FDA approval requirements, manufacturing know-how, supply economics, and product-specific bioequivalence rather than by a blocking U.S. composition-of-matter patent.
U.S. patent and Orange Book position
| Issue |
Current commercial assessment |
| Nitrofurantoin compound patent |
Expired |
| Original Macrobid formulation protection |
Expired |
| Current U.S. Orange Book blocking estate |
No material active exclusivity identified for routine generic entry |
| Generic pathway |
ANDA with demonstrated pharmaceutical equivalence and bioequivalence |
| Formulation patent risk |
Possible only for newly developed differentiated products |
| Method-of-use patent risk |
Limited for the established cystitis indication |
| Litigation risk |
Historically relevant during initial generic entry; not a current barrier to ordinary generic supply |
The FDA Orange Book remains the controlling source for listed patents and exclusivity associated with approved U.S. drug products. Historical patent listings should be checked against the relevant NDA and patent-use codes because expired listings and legacy litigation records can otherwise distort the competitive analysis. [2]
When did nitrofurantoin monohydrate/macrocrystals lose exclusivity?
Nitrofurantoin monohydrate/macrocrystals lost practical U.S. exclusivity years ago. Macrobid has long been subject to generic competition, and multiple manufacturers have marketed 100 mg capsules.
| Milestone |
Commercial significance |
| Original Macrobid approval |
Established the monohydrate/macrocrystals reference formulation |
| Expiration of formulation patent protection |
Opened the market to ANDA competition |
| Generic approvals |
Shifted competition toward cost, supply, and bioequivalence |
| Current market |
Mature, multi-source antibiotic market |
The relevant commercial question is not whether a generic can enter. It is whether a new supplier can meet FDA quality standards at a sustainable cost while maintaining dependable active-ingredient and capsule-component supply.
Are Paragraph IV challenges still relevant for Macrobid?
Paragraph IV litigation was relevant when generic companies challenged unexpired Macrobid patent listings. It is not the principal current barrier to standard nitrofurantoin monohydrate/macrocrystals entry because the core product and historical formulation patents are expired.
A Paragraph IV strategy could become relevant again if a company launches a new protected product, such as:
- A novel extended-release formulation.
- A new pediatric dosage form.
- A differentiated multiparticulate product.
- A formulation with a protected excipient system.
- A new indication or dosing regimen.
- A combination product.
For the established 100 mg capsule, the main legal work is usually ANDA certification, patent-history review, labeling conformity, and quality documentation rather than offensive patent litigation.
What is the FDA regulatory status of nitrofurantoin monohydrate/macrocrystals?
Nitrofurantoin monohydrate/macrocrystals is an FDA-approved prescription oral capsule product. Generic versions are approved through the ANDA pathway when they demonstrate pharmaceutical equivalence and bioequivalence to the reference listed drug. [1,2]
Regulatory development considerations
A generic developer should address:
- Active-ingredient characterization.
- Drug-product sameness.
- Capsule strength and dosage-form equivalence.
- Dissolution method suitability.
- Fed and fasting bioequivalence requirements.
- Stability under ICH conditions.
- Impurity control.
- Manufacturing-process validation.
- Labeling consistency.
- Supplier qualification for nitrofurantoin and critical excipients.
Because nitrofurantoin has low solubility and food-dependent administration, dissolution development deserves particular attention. A formulation that passes a basic quality screen but shows a different release profile under physiologically relevant conditions may create bioequivalence or post-approval risk.
How strong is the patent estate for nitrofurantoin monohydrate/macrocrystals?
The legacy patent estate is weak as a current market barrier. Its commercial strength is low because the principal formulation concepts and the reference product’s market exclusivity period have expired.
A new patent estate could be stronger if it protects measurable product attributes that are difficult to design around, such as:
- A narrow particle-size distribution linked to dissolution.
- A defined monohydrate-to-macrocrystal ratio.
- A specific multiparticulate architecture.
- A novel coating that controls release or gastric exposure.
- A stable, low-moisture composition.
- A pediatric liquid or dispersible dosage form.
- A manufacturing process that produces a distinctive solid-state profile.
Patentability remains difficult for routine excipient substitutions. Claims covering lactose replacement, standard capsule materials, or conventional lubricants may face obviousness challenges unless supported by unexpected performance data.
What formulation patents could support a new nitrofurantoin product?
The most defensible formulation patents would connect composition to a defined technical result. Examples include:
| Potential patent focus |
Evidence needed |
| Reduced food-effect variability |
Comparative pharmacokinetic data |
| Improved dissolution of poorly soluble nitrofurantoin |
Discriminatory dissolution and in vivo correlation |
| Lower gastrointestinal intolerance |
Comparative clinical or pharmacodynamic evidence |
| Stable lactose-free composition |
Long-term and accelerated stability |
| Pediatric dispersible dosage form |
Dose uniformity, palatability, stability, and bioavailability |
| Once-daily release system |
Pharmacokinetic and clinical data |
| Moisture-resistant capsule |
Packaging and stability data |
| Improved powder-flow process |
Scale-up data, content uniformity, and process capability |
Process patents may have commercial value even where they do not block all generic products. A process that lowers scrap, improves yield, or reduces blend-segregation risk can produce a cost advantage.
Which companies are competing in nitrofurantoin monohydrate/macrocrystals?
The market includes the Macrobid reference product and multiple generic manufacturers and marketers. Company participation changes over time because suppliers enter, exit, transfer approvals, or source the product from contract manufacturers.
Competition generally divides into four groups:
- Branded or authorized-generic suppliers.
- Large generic pharmaceutical companies.
- Regional generic manufacturers.
- Contract manufacturers supplying private-label or institutional channels.
The most important competitive variables are:
- Reliable nitrofurantoin API supply.
- FDA inspection history and manufacturing compliance.
- Product availability during antibiotic shortages.
- Wholesale acquisition cost.
- Contract pricing.
- National drug-code coverage.
- Packaging flexibility.
- Ability to supply hospitals and public-health tenders.
- International registration capability.
The FDA Drugs@FDA database, Orange Book, DailyMed, and FDA drug-shortage resources should be used to confirm the current supplier set and product availability. [2-4]
What commercial opportunities exist beyond the standard capsule?
Geographic expansion
Emerging-market opportunities may exist where urinary-tract-infection treatment remains dependent on imported antibiotics and where nitrofurantoin stewardship is favored over broader-spectrum agents. Registration strategy must account for local rules on:
- Nitrofurantoin monohydrate versus macrocrystalline nomenclature.
- Capsule strength.
- Renal-function labeling.
- Pregnancy and pediatric use.
- Bioequivalence evidence.
- Excipient acceptability.
- Local pharmacopoeial standards.
Institutional and public procurement
Hospitals, correctional systems, public-health programs, and national tenders often prioritize dependable supply and low total cost. A supplier with validated dual sourcing and strong shortage-management capability can win contracts without changing the formulation.
Packaging differentiation
Unit-dose blister packs, calendar packs, and clear administration instructions may improve adherence and reduce dispensing errors. Packaging patents are usually weaker than formulation patents, but packaging can produce a practical commercial advantage.
Pediatric formulations
A pediatric product could address swallowing barriers, but the opportunity requires careful positioning. Nitrofurantoin use in children depends on age, indication, renal function, and local labeling. A liquid, dispersible tablet, or multiparticulate product would require robust dose uniformity, palatability, stability, and bioequivalence data.
Veterinary and nonhuman applications
Veterinary opportunities require separate regulatory analysis and are not automatically supported by the human product’s approval or safety profile. The strongest near-term opportunity remains human generic and institutional supply.
How does nitrofurantoin compare with other urinary-tract-infection products?
| Product |
Main commercial position |
Formulation opportunity |
Key limitation |
| Nitrofurantoin monohydrate/macrocrystals |
Narrow-spectrum treatment for uncomplicated cystitis |
Lactose-free, pediatric, moisture-robust, adherence-focused products |
Not suitable for pyelonephritis or systemic infection |
| Nitrofurantoin macrocrystals |
Older nitrofurantoin formulation |
Lower-cost generic supply |
More frequent dosing and tolerability considerations |
| Fosfomycin tromethamine |
Single-dose oral option in selected cases |
Taste, sachet, and formulation convenience |
Resistance and indication-specific positioning |
| Trimethoprim-sulfamethoxazole |
Established oral antibiotic |
Cost and fixed-dose packaging |
Resistance and contraindication concerns |
| Fluoroquinolones |
Broad-spectrum agents |
Limited formulation differentiation |
Stewardship and safety restrictions |
Nitrofurantoin’s commercial strength is its focused use in uncomplicated cystitis and its role in antibiotic stewardship. Its weakness is that the product has limited use outside the lower urinary tract.
What generic launch risks exist?
Generic launch risk is moderate operationally and low from a basic patent-barrier perspective.
Principal risks
- Failure to match reference-product dissolution.
- API variability or inadequate particle-size control.
- Capsule-fill segregation.
- Supplier concentration for specialized nitrofurantoin grades.
- FDA inspection findings.
- Product recalls caused by content-uniformity or stability failures.
- Price erosion in a multi-source market.
- Contract loss from unreliable supply.
- Renal-function or labeling discrepancies.
- Market withdrawal by low-margin suppliers.
The most credible launch strategy is a quality-focused, low-cost product with dual-sourced raw materials, validated blend control, and packaging suitable for high-humidity markets.
What licensing deals and partnership structures are available?
Because the core product is generic, licensing value is more likely to arise from manufacturing, regional commercialization, or differentiated formulations than from the base molecule.
Potential transaction structures include:
- Regional rights for an approved generic.
- Authorized-generic supply agreements.
- Contract manufacturing with technology transfer.
- Co-development of a pediatric or modified-release product.
- API supply agreements with minimum-volume commitments.
- Private-label distribution for institutional customers.
- Licensing of a moisture-resistant or lactose-free formulation.
- Acquisition of an approved ANDA and associated manufacturing network.
Royalty economics for a standard 100 mg capsule are likely to be constrained by generic price competition. A differentiated product with clinical or adherence data could support stronger economics but would require materially higher development expenditure.
What revenue exposure does nitrofurantoin create for manufacturers?
Revenue exposure is generally limited for companies with broad generic portfolios, but it can be material for a focused supplier or contract manufacturer. The product is inexpensive, repeat-prescribed, and volume-driven. Revenue depends on:
- Prescription volume.
- Reimbursement and tender pricing.
- Number of active competitors.
- Supply continuity.
- API cost.
- Manufacturing yield.
- Channel mix.
- Geographic registration footprint.
Public-company disclosures rarely isolate nitrofurantoin revenue. Product-level estimates based only on prescription counts or wholesale data should be treated carefully because manufacturer net sales, rebates, chargebacks, and private-label transfers are not fully visible in public sources.
Key Takeaways
- Nitrofurantoin monohydrate/macrocrystals is a mature generic market centered on 100 mg capsules.
- The reference Macrobid formulation uses conventional excipients, including lactose monohydrate, corn starch, povidone, magnesium stearate, and talc.
- Particle size, solid-state form, blend uniformity, wetting, and dissolution are more important than simple excipient matching.
- Historical Macrobid patent protection has expired, and no material current Orange Book barrier prevents ordinary generic entry.
- Commercial opportunities include lactose-free capsules, vegetarian shells, pediatric dosage forms, moisture-robust packaging, institutional supply, and regional expansion.
- Routine excipient substitutions are unlikely to support strong patent protection without unexpected performance data.
- The principal risks are bioequivalence failure, API and excipient variability, manufacturing quality, supply disruption, and generic price erosion.
- A new modified-release or pediatric product would require a separate regulatory, clinical, and patent strategy.
FAQs
Is nitrofurantoin monohydrate/macrocrystals the same as Macrobid?
Macrobid is the reference brand associated with nitrofurantoin monohydrate/macrocrystals capsules. Approved generics must meet applicable pharmaceutical-equivalence and bioequivalence requirements.
Can lactose be removed from nitrofurantoin monohydrate/macrocrystals?
Yes. Lactose can potentially be replaced with excipients such as microcrystalline cellulose, mannitol, or pregelatinized starch, but the revised product must demonstrate acceptable dissolution, stability, content uniformity, and bioequivalence.
Does nitrofurantoin monohydrate/macrocrystals require a formulation patent?
No. A standard generic capsule can rely on the ANDA pathway without a new formulation patent, provided it meets FDA requirements and does not infringe an unexpired listed patent.
Could a once-daily nitrofurantoin product obtain new exclusivity?
Potentially, but a once-daily product would require a novel release design and supporting pharmacokinetic and clinical evidence. Any new exclusivity would depend on the specific regulatory pathway and patent claims.
What is the most attractive near-term commercial niche?
The strongest near-term niches are reliable institutional supply, private-label manufacturing, export markets requiring robust humidity stability, and differentiated capsules that address lactose, vegetarian-shell, or swallowing preferences without materially increasing production cost.
References
- U.S. Food and Drug Administration. (2024). Macrobid: Nitrofurantoin monohydrate/macrocrystals capsule prescribing information. DailyMed.
- U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book.
- U.S. Food and Drug Administration. (2024). Drugs@FDA: FDA-approved drugs database.
- U.S. Food and Drug Administration. (2024). Drug shortages database.
- United States Pharmacopeial Convention. (2024). United States Pharmacopeia and National Formulary: Nitrofurantoin monohydrate/macrocrystals.
